MET and cancer: Currently, research results indicated that HGF/Met signaling could support mechanisms for immune escape of cancer cells, so new approaches are being developed, to combine MET and programmed cell death receptor-1 (PD-1)/programmed cell death receptor-ligand 1 (PD-L1) inhibition in drug design and targeted therapy [25, 26].